Which is better, EXEL or JSLL.NS?

On the Buffett-Fit framework, JEENA SIKHO LIFECARE LTD (JSLL.NS) currently grades higher than EXEL — 84/100 (A grade) vs 64/100 (C). That said, "better" depends on which framework you trust — EXEL wins on none; JSLL.NS wins on Warren Buffett, Benjamin Graham, Philip Fisher, Peter Lynch, Joel Greenblatt, Charlie Munger, and Terry Smith. The full pillar breakdown is on this page.

Should I buy EXEL or JSLL.NS?

This page is an educational comparison, not investment advice. Both EXEL and JSLL.NS are graded against the same Buffett 5-pillar framework (moat, earnings durability, management quality, financial health, valuation) plus six other documented investor frameworks. Read the side-by-side breakdown to see which one matches the criteria you care about most — and always do your own research before making any investment decision.

Is EXEL better than JSLL.NS for value investing?

On the Buffett-style value-investing framework, JSLL.NS currently grades higher — 84/100 vs 64/100, a 20-point gap. The gap is driven by which pillars each stock passes; the table on this page shows moat, durability, management, financial health, and valuation side-by-side.

What's the difference between EXEL and JSLL.NS on Warren Buffett's framework?

Both stocks are evaluated on the same five pillars: economic moat (durable competitive advantage), earnings durability (consistent profitability), management quality (capital allocation), financial health (conservative balance sheet), and valuation (margin of safety). EXEL currently scores 64/100 (C grade); JSLL.NS scores 84/100 (A grade). The "Where each wins" section on this page breaks down which pillar each stock dominates.

Which has the stronger moat, EXEL or JSLL.NS?

Moat strength is one of the five pillars in the Buffett-Fit score on this page. EXEL and JSLL.NS are each scored on ROIC sustainability, gross-margin durability, and qualitative signals like brand strength, switching costs, network effects, and regulatory barriers. The pillar breakdown on this page shows the moat sub-score side-by-side so you can see which one has the more durable competitive advantage.

Which is more undervalued, EXEL or JSLL.NS?

Valuation is one of the five Buffett-Fit pillars on this page. Both stocks are scored on owner-earnings yield, price-to-intrinsic-value vs the underlying compounding rate, and the margin of safety relative to a conservative DCF. The valuation sub-score in the table below tells you which one currently trades at a more attractive price relative to its underlying business quality.

Are EXEL and JSLL.NS both Healthcare stocks?

Yes — both Exelixis, Inc. (EXEL) and JEENA SIKHO LIFECARE LTD (JSLL.NS) operate in the Healthcare sector. That makes this a direct sector-peer comparison, which is the apples-to-apples way to use the Buffett-Fit framework: the score weighs each stock against its sector's specific quality and valuation benchmarks (sector-relative bonus), so the cross-stock comparison isn't distorted by inter-sector base-rate differences.

Is this EXEL vs JSLL.NS comparison investment advice?

No. This page is an educational pattern-match against documented public frameworks (Buffett, Graham, Fisher, Lynch, Greenblatt, Munger, Smith), not personalised investment advice. The scores reflect how closely each stock matches each framework's documented criteria — they are not buy/hold/sell recommendations. Always do your own research and consult a licensed financial adviser for personalised advice.

Stock comparison

Exelixis

EXEL$13.77BHealthcare Market cap, Sector

JEENA SIKHO LIFECARE

JSLL.NS$74.83BHealthcare Market cap, Sector

Overall winner

JEENA SIKHO LIFECARE

EXEL 07 JSLL.NS

Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.

Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.

Fit scores by strategy

EXEL0wins

7winsJSLL.NS

Warren Buffett

64C

B84

Benjamin Graham

74B

A87

Philip Fisher

74B

A92

Peter Lynch

58D

C66

Joel Greenblatt

60C

B75

Charlie Munger

71B

A91

Terry Smith

80B

A95

Side-by-side metrics

Metric	EXEL	JSLL.NS
Market cap	$13.77B	$74.83B Winner
P/E (TTM)	Winner: 15.5x	33.3x
EV/EBIT	Winner: 14.3x	24.1x
ROIC (TTM)	35.01%	39.15% Winner
Gross margin	Winner: 96.44%	88.58%
Net margin	Winner: 35.08%	27.68%
Revenue CAGR 5y	12.76%	57.81% Winner
EPS CAGR 5y	40.93%	86.67% Winner
Debt / Equity	Winner: 0.1x	0.3x
Dividend yield	0.0%	-

Where each one wins

The metrics with the biggest gap between the two - sorted so the most decisive edges read first.

EXEL leads on

Debt / Equity0.1xvs 0.3x+68%
P/E (TTM)15.5xvs 33.3x+53%
EV/EBIT14.3xvs 24.1x+41%
Net margin35.08%vs 27.68%+21%

JSLL.NS leads on

Market cap$74.83Bvs $13.77B+82%
Revenue CAGR 5y57.81%vs 12.76%+78%
EPS CAGR 5y86.67%vs 40.93%+53%
ROIC (TTM)39.15%vs 35.01%+11%

More like EXEL

EXEL vs JSLL.BO EXEL vs 4728.TWO EXEL vs PME.AX EXEL vs CAMX.ST

More like JSLL.NS

JSLL.NS vs JSLL.BO JSLL.NS vs 4728.TWO JSLL.NS vs PME.AX JSLL.NS vs CAMX.ST

Read the full Buffett-Brain analysis for EXEL Read the full Buffett-Brain analysis for JSLL.NS

Related on invest-like

Strongest Moat Highest ROIC Warren Buffett strategy Economic Moat

Key terms in this analysis

ROIC Free Cash Flow (FCF)Economic Moat P/E Ratio Margin of Safety Quality Score

Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.

Stock comparison

Exelixis

EXEL$13.77BHealthcare Market cap, Sector

JEENA SIKHO LIFECARE

JSLL.NS$74.83BHealthcare Market cap, Sector

Overall winner

JEENA SIKHO LIFECARE

EXEL 07 JSLL.NS

Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.

Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.

Fit scores by strategy

EXEL0wins

7winsJSLL.NS

Warren Buffett

64C

B84

Benjamin Graham

74B

A87

Philip Fisher

74B

A92

Peter Lynch

58D

C66

Joel Greenblatt

60C

B75

Charlie Munger

71B

A91

Terry Smith

80B

A95

Side-by-side metrics

Metric	EXEL	JSLL.NS
Market cap	$13.77B	$74.83B Winner
P/E (TTM)	Winner: 15.5x	33.3x
EV/EBIT	Winner: 14.3x	24.1x
ROIC (TTM)	35.01%	39.15% Winner
Gross margin	Winner: 96.44%	88.58%
Net margin	Winner: 35.08%	27.68%
Revenue CAGR 5y	12.76%	57.81% Winner
EPS CAGR 5y	40.93%	86.67% Winner
Debt / Equity	Winner: 0.1x	0.3x
Dividend yield	0.0%	-

Where each one wins

The metrics with the biggest gap between the two - sorted so the most decisive edges read first.

EXEL leads on

Debt / Equity0.1xvs 0.3x+68%
P/E (TTM)15.5xvs 33.3x+53%
EV/EBIT14.3xvs 24.1x+41%
Net margin35.08%vs 27.68%+21%

JSLL.NS leads on

Market cap$74.83Bvs $13.77B+82%
Revenue CAGR 5y57.81%vs 12.76%+78%
EPS CAGR 5y86.67%vs 40.93%+53%
ROIC (TTM)39.15%vs 35.01%+11%

More like EXEL

EXEL vs JSLL.BO EXEL vs 4728.TWO EXEL vs PME.AX EXEL vs CAMX.ST

More like JSLL.NS

JSLL.NS vs JSLL.BO JSLL.NS vs 4728.TWO JSLL.NS vs PME.AX JSLL.NS vs CAMX.ST

Read the full Buffett-Brain analysis for EXEL Read the full Buffett-Brain analysis for JSLL.NS

Related on invest-like

Strongest Moat Highest ROIC Warren Buffett strategy Economic Moat

Key terms in this analysis

ROIC Free Cash Flow (FCF)Economic Moat P/E Ratio Margin of Safety Quality Score

Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.